Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus-Reference-Cited by-同舟云学术

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus

Published:2024-03-21 Issue:4 Volume:14 Page:919-932
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Gargiulo Luigi,Ibba Luciano^ORCID,Malagoli Piergiorgio,Burroni Anna G.,Chiricozzi Andrea,Dapavo Paolo,Ferrucci Silvia M.,Gola Massimo,Napolitano Maddalena,Ortoncelli Michela,Rossi Maria T.,Sciarrone Claudio,Costanzo Antonio,Narcisi Alessandra

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13555-024-01135-x.pdf

Reference39 articles.

1. Ali F, Vyas J, Finlay AY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol. 2020;100(12):00161. https://doi.org/10.2340/00015555-3511.

2. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–51. https://doi.org/10.1016/j.jaad.2013.10.010.

3. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I-systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–31. https://doi.org/10.1111/jdv.18345.

4. Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157:1047–55.

5. Gargiulo L, Ibba L, Cortese A, et al. Real-life effectiveness and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: a single-center 16-week study. Dermatol Ther (Heidelb). 2023;13:651–60.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of nemolizumab in the treatment of atopic dermatitis for the adult population;Immunotherapy;2024-08-09

2. Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study;Journal of Dermatological Treatment;2024-07-04

3. Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options;Journal of Investigative Dermatology;2024-07

4. Utilisation des médicaments systémiques dans le traitement de la dermatite atopique modérée à sévère de l’adulte;Annales de Dermatologie et de Vénéréologie - FMC;2024-06

5. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-05-17